Document is current
Any future updates will be listed below
-
Authors
Braczko, Felix https://orcid.org/0000-0002-5929-052X
Skyschally, Andreas https://orcid.org/0000-0001-8396-0450
Lieder, Helmut https://orcid.org/0000-0001-8631-3355
Kather, Jakob Nikolas https://orcid.org/0000-0002-3730-5348
Kleinbongard, Petra https://orcid.org/0000-0003-3576-3772
Heusch, Gerd https://orcid.org/0000-0001-7078-4160
-
Funding
Funding for this research was provided by:
European Union COST Action EU-METAHEART (CA22169)
European Union COST Action CA-METAHEART (CA22169)
European Union COST Action CARDIOPROTECTION (CA16225, CA16225, IGI16225, IGI16225)
Deutsche Forschungsgemeinschaft (CRC 1116 B8, CRC 1116 B8, RTG 2989 P5, RTG 2989 P5)
GSK
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Received: 4 June 2024
Revised: 5 September 2024
Accepted: 23 September 2024
First Online: 30 September 2024
Declarations
:
: FB, AS, HL, PK, GH: no disclosures. JNK: consulting services for Bioptimus, France; Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK; AstraZeneca, UK; Scailyte, Switzerland; Mindpeak, Germany; and MultiplexDx, Slovakia; shareholder StratifAI GmbH, Germany; Synagen GmbH, Germany; honoraria by AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Janssen, MSD, BMS, Roche, Pfizer and Fresenius.
